Strata Oncology has announced it has secured $26 million in series B funding.

Strata, based in Ann Arbor, Mich., describes itself as a precision oncology platform company.

New investors in the company were Pfizer Ventures, Merck Global Health Innovation Fund, Deerfield Management and Renaissance Venture Capital Fund. They joined existing investors Arboretum Ventures and Baird Capital.

Strata indicated it intends to use the latest round of funding for multiple purposes, including expanding its client base and further developing solutions.